Your donation will make a difference:
Cystic Fibrosis Trust

Trials Tracker

Due to COVID-19 some cystic fibrosis (CF) clinical trials may be still be temporarily paused, however some trials will begin to re-open soon. If you have any questions about taking part in clinical trials, please speak to our CF team or contact the Trust’s clinical trial team. Please also see the relevant advice on the COVID-19 Q&A page. The Trials Tracker brings together all CF trials currently recruiting in the UK, so you can find clinical trials you can take part in both in your region and further afield

Please Log in

Log in

Not a registered user? Register with us

This trial has been added to your watchlist.

Do you want to receive email notifications when the trial status changes?

No Yes

Unfollowing a trial will remove it from the watchlist and stop status change email notifications

Are you sure you want to unfollow this trial?

Yes, remove from watchlist

Clinical trials

61-63 of 63 results for all trials

Sort by:

Filter by

Therapeutic category

Trial status


The purpose of this study is to find out whether GLPG2222, taken by mouth as tablet once a day, is safe, well-tolerated and effective in improving your signs and symptoms of cystic fibrosis. The study will also evaluate how the body takes in and breaks down the study drug (GLPG2222). The amount of drug in your blood will be measured at specific study visits after you start taking the drug. These measurements will show how quickly the drug is taken up by the body, how quickly it is broken down, when it reaches a steady level in the blood, and how long it stays in the body

Read more Phase II
  • Trial Reference Number


  • Mutation

    Two copies of F508del (delta F508)

  • Age


  • Length of participation

    6 - 10 weeks

  • Trial status

    Closed to recruitment - in follow up

  • Therapeutic category

    Restore CFTR Function


The primary objective of this study is to evaluate the safety and efficacy of a 14-day course versus a 28-day course of aztreonam for inhalation solution (AZLI) in participants with new onset Pseudomonas aeruginosa respiratory tract infection.

Phase III
  • Trial Reference Number


  • Length of participation

    28 days

  • Trial status

    Closed to recruitment - in follow up

  • Therapeutic category


MAGIC- a self-management education programme for people with CFRD

Cystic fibrosis related diabetes (CFRD) is the most common complication of CF, affecting 45-50% of adults. CFRD is different from type 1 and 2 diabetes and needs specialist dietary and clinical management. CFRD has a significant effect on nutrition, lung function and survival. The need to educate people with CFRD is important because, keeping blood glucose controlled results in improvements in nutrition, and reduces the development of long term complications from CFRD, including death. NICE recommends that everyone with diabetes should be offered a place on a diabetes self-management education (DSME) programme. However, there are currently no DSME programmes specifically for people with CFRD and there is little evidence to base them on. This study, informed by the Medical Research Council’s framework for developing complex interventions, aims to develop an evidence-based self-management education programme for people with CFRD that, will be called MAGIC (Managing Abnormal Glucose In Cystic fibrosis). Stage one is a synthesis of qualitative studies and qualitative patient interviews. This will identify patients’ experiences of living with CFRD and their barriers and facilitators to CFRD self-management. It will help establish what educational input people with CFRD want and identify the skills and knowledge people with CFRD require. Stage one will inform stage two. Stage two is the development of the MAGIC programme by a working group of lay members and healthcare professionals. The MAGIC programme will be evaluated with ten CFRD patients within the hospital. This will help inform future studies required to evaluate its effectiveness (feasibility study), and if appropriate a randomised control trial for evaluating the cost-effectiveness and the impact on well-being and survival of the MAGIC programme at a national level.

Read more Not Applicable
  • Trial Reference Number


  • Length of participation

    2 days

  • Trial status

    Closed - follow up complete

  • Therapeutic category


61-63 of 63 results for all trials